Together, our results indicate that a sustained dephosphorylation of ALK at multiple phosphorylation sites by both crizotinib and ceritinib can be detected quantitatively by immunoassay in neuroblastoma cell lines with ALK mutations at F1174L or R1275Q. This evidence concerns the gene ALK and neuroblastoma.